Scholarlink

<p>The purpose of this study was to comprehensively analyze the prediction role of NADPH oxidase (NOX)-related polymorphisms (<i>NCF4</i>: rs1883112, <i>CYBA</i>: rs4673, <i>RAC2</i>: rs13058338) and immunohistochemical indices on survival in diffuse large B-cell lymphoma (DLBCL).The impact of NOX polymorphisms were evaluated in 335 DLBCL patients treated with R (rituximab)-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) from Harbin Medical University Cancer Hospital. We also collected information on their immunohistochemical expression and clinical outcomes.Among the patients treated with R-CHOP therapy, the patients with CyclinD1 (+) had significantly shorter progression-free survival (PFS) (<i>p</i> = 0.001) and event-free survival (EFS) (<i>p</i> &lt; 0.001) than CyclinD1 (-) patients. Among patients received CHOP therapy, PFS was significantly longer in CD20 (+) patients (<i>p</i> = 0.011) than in CD20(-) patients. Among the patients treated with R-CHOP therapy, the PFS (<i>p</i> = 0.020) and EFS (<i>p</i> &lt; 0.001) of patients with <i>NCF4</i> rs1883112 AA/AG genotype were significantly longer than the patients with GG genotype. Patients treated with R-CHOP therapy and with <i>RAC2</i> rs13058338 AA/AT genotype were more likely to have grade III or higher myelosuppression compared to patients with TT genotype (<i>p</i> = 0.027). Patients treated with CHOP therapy and with <i>RAC2</i> rs13058338 AA/AT genotype were more likely to have grade III or higher systemic adverse events (<i>p</i> = 0.029). Cox regression analysis showed that <i>NCF4</i> rs1883112 GG genotype and CyclinD1 (+) were the factors contributing to the poor outcomes in DLBCL patients treated with R-CHOP therapy.In conclusion, the results suggested that the <i>NCF4</i> rs1883112 G allele may be a poor prognostic biomarker, especially for the DLBCL patients with CD3(-), CD5 (-), CD10 (-), Bcl-2 (+), Bcl-6 (+) or Ki-67(%) &lt; 80%.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The association between NADPH oxidase (NOX) polymorphisms with immunohistochemistry and survival in diffuse large B cell lymphoma patients

  • 期刊论文

  • 发表日期：

    2025年1月8日

查看全文
  • Chao Chen,
  • Quan Dong,
  • Huiqi Wang,
  • Shiqi Dong,
  • Shufan Wang,
  • Wenxin Lin,
  • Chuiming Jia,
  • Mei Dong,
  • Yan Jin,
  • Duo Liu

摘要

The purpose of this study was to comprehensively analyze the prediction role of NADPH oxidase (NOX)-related polymorphisms (NCF4: rs1883112, CYBA: rs4673, RAC2: rs13058338) and immunohistochemical indices on survival in diffuse large B-cell lymphoma (DLBCL).The impact of NOX polymorphisms were evaluated in 335 DLBCL patients treated with R (rituximab)-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) from Harbin Medical University Cancer Hospital. We also collected information on their immunohistochemical expression and clinical outcomes.Among the patients treated with R-CHOP therapy, the patients with CyclinD1 (+) had significantly shorter progression-free survival (PFS) (p = 0.001) and event-free survival (EFS) (p < 0.001) than CyclinD1 (-) patients. Among patients received CHOP therapy, PFS was significantly longer in CD20 (+) patients (p = 0.011) than in CD20(-) patients. Among the patients treated with R-CHOP therapy, the PFS (p = 0.020) and EFS (p < 0.001) of patients with NCF4 rs1883112 AA/AG genotype were significantly longer than the patients with GG genotype. Patients treated with R-CHOP therapy and with RAC2 rs13058338 AA/AT genotype were more likely to have grade III or higher myelosuppression compared to patients with TT genotype (p = 0.027). Patients treated with CHOP therapy and with RAC2 rs13058338 AA/AT genotype were more likely to have grade III or higher systemic adverse events (p = 0.029). Cox regression analysis showed that NCF4 rs1883112 GG genotype and CyclinD1 (+) were the factors contributing to the poor outcomes in DLBCL patients treated with R-CHOP therapy.In conclusion, the results suggested that the NCF4 rs1883112 G allele may be a poor prognostic biomarker, especially for the DLBCL patients with CD3(-), CD5 (-), CD10 (-), Bcl-2 (+), Bcl-6 (+) or Ki-67(%) < 80%.